Evolving algorithm for treating male voiding symptoms
The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
This article is part of the State of Urology 2013
The algorithm for urologists’ approach to male voiding symptoms is evolving, according to Steven A. Kaplan, MD, of Weill Cornell Medical College, New York. This will be evident in presentations on BPH and lower urinary tract symptoms at the AUA annual meeting.
In addition, watch for presentations on the continuing evolution of mechanisms for new medical agents for BPH and a clearer picture of retreatment rates for ablative therapies, including monopolar and bipolar plasma vaporization and Thulium vaporesection.
Specifically, here are Dr. Kaplan’s top abstract choices from this year’s meeting:
1384: Testosterone Supplementation Does Not Worsen Lower Urinary Tract Symptoms
Jeffrey Pearl
1965: Three-year prospective, randomized comparison of the bipolar plasma vaporization of the prostate, monopolar and bipolar resection in medium size BPH patients
Bogdan Geavlete
1967: Small resected prostate weight is associated with a higher reoperation rate following transurethral resection of the prostate ¡V A study on 33905 patients
Alex Tong Long Lin
1733: Candidate gene association studies of lower urinary tract symptoms in men: a systematic review and meta-analysis
Kari Tikkinen
1739: The association of suicidal ideation, depression and lower urinary tract symptoms, data from the National Health and Nutrition Examination Survey (NHANES), 2005-2006 and 2007-2008
Benjamin Breyer
1740: Genetics variants that increase severe lower urinary tract symptoms in African-American men
Brian T. Helfand
2183: Long-term Outcome Following Thulium VapoEnucleation Of The Prostate
Christopher Netsch
Also keep an eye out for late-breaking abstracts on the Prostatic Urethral Lift (NeoTract, Inc., Pleasanton, CA) for LUTS associated with BPH and the role of enclomiphene as a therapy in men with secondary hypogonadism.UT
Destigmatizing Urology: Dr. Winter discusses STDs/STIs
March 22nd 2022“We need to just approach STIs as the medical conditions they are because until we do, and until we take those stigmas away, people will truly have resistance to discussing it, hesitance to discussing it, and resistance to diagnosis and intervention,” says Ashley Winter, MD.
